The Japanese Association for Thoracic Surgery has conducted annual surveys of thoracic surgery throughout Japan since 1986 to determine the statistics regarding the number of procedures according to operative category. Here, we have summarized the results from our annual survey of thoracic surgery performed during 2013.

The incidence of hospital mortality was added to the survey to determine the nationwide status, which has contributed to the Japanese surgeons to understand the present status of thoracic surgery in Japan and to make progress to improve operative results by comparing their work with those of others. The Association was able to gain a better understanding of present problems as well as future prospects, which has been reflected to its activity including education of its members. Thirty-day mortality (so called "operative mortality") is defined as death within 30 days of operation regardless of the patient's geographic location and even though the patient had been discharged from the hospital.

Hospital mortality is defined as death within any time interval after an operation if the patient had not been discharged from the hospital. Hospital-to-hospital transfer is not considered discharge: transfer to a nursing home or a rehabilitation unit is considered hospital discharge unless the patient subsequently dies of complications of the operation. (The definitions of the Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity of the Society of Thoracic Surgeons and the American Association for Thoracic Surgery (Edmunds et al. Ann Thorac Surg 1996;62:932--5; J Thorac Cardiovasc Surg 1996;112:708--11).

Thoracic surgery was classified into three categories---cardiovascular, general thoracic, and esophageal surgery---and the patient data were examined and analyzed for each group. Access to the computerized data is offered to all members of this Association. We honor and value all member's continued kind support and contributions (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}).**Table 1** Questionnaires sent out and received back by the end of December 2014Sent outReturnedResponse rate (%)(A) Cardiovascular surgery60258997.8(B) General thoracic surgery79376196.0(C) Esophageal surgery57755996.9 **Table 2** Categories subclassified according to the number of operations performedNumber of operations performedCategoryCardiovascular surgeryGeneral thoracic surgery044341--244410125--499212550--99172210100--14986124150--1995683≧2009585Total589762Number of operations performedEsophageal surgery0841--4965--98410--1910920--295630--393540--4926≧5069Total559

Abstract of the survey {#Sec1}
======================

We sent out survey questionnaire forms to the departments of each category in all 1535 institutions (602 cardiovascular, 793 general thoracic and 577 esophageal) nationwide in early April 2014. The response rates in each category by the end of December 2014 were 97.8, 96.0, and 96.9 %, respectively. This high response rate has been keep throughout recent survey, and more than 96 % response rate in all fields in 2013 survey has to be congratulated.

2013 Final report {#Sec2}
=================

(A) Cardiovascular surgery {#Sec3}
--------------------------

First, we are very pleased with the high response rate to our survey of cardiovascular surgery (97.8 %), which definitely enhances the quality of this annual report. We very much appreciate the enormous effort put into completing the survey at each participating institution.

Figure [1](#Fig1){ref-type="fig"} shows the development of cardiovascular surgery in Japan over the last 27 years. Aneurysm surgery includes only operations for thoracic and thoracoabdominal aortic aneurysm. Pacemaker implantation includes only trans-thoracic implantation and trans-venous implantation is excluded. The number of pacemaker and assist device implantation operations is not included in the total number of surgical operations. A total of 67,325 cardiovascular operations were performed at 589 institutions during 2013 alone and included 36 heart transplantations, which were re-started in 1999, and 1 heart and lung transplantation.Fig. 1Cardiovascular surgery. *IHD* ischemic heart disease

The number of operations for congenital heart disease (9366 cases) decreased slightly (2.0 %) compared with that of 2012 (9558 cases), while there was 2.1 % increase when compared with the data of 10 years ago (9168 cases in 2003). The number of operations for adult cardiac disease (21,758 cases in valvular heart disease, 15,757 cases in thoracic aortic aneurysm and 1871 cases for other procedures) increased compared with those of 2012 (4.0, 4.6 and 14.6 %, respectively) except for ischemic heart disease (16,752 cases,) which decreased 1.9 % of that in 2012. During the last 10 years, the numbers of operations for adult heart disease increased constantly except for that for ischemic heart disease (83.4 % increase in valvular heart disease, 25.4 % decrease in ischemic heart disease, 120.9 % increase in thoracic aortic aneurysm, and 45.7 % increase in other procedures compared those of 2003). The concomitant coronary artery bypass grafting procedure (CABG) is not included in ischemic heart disease but included in other categories such as valvular heart disease and thoracic aneurysm in our study; then, the number of CABG still remained over 20,000 cases per year (21,242 cases) in 2013, which is 87.8 % of that in 2003 (24,204 cases).

Data for individual categories are summarized in tables through [3](#Tab3){ref-type="table"} to [9](#Tab23){ref-type="table"}.**Table 3** Congenital (total; 9366)(1) CPB (+) (total; 7150)NeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1PDA300010 0 0 20 0 0 141 (7.1)0 1 (7.1)201 (5.0)0 1 (5.0)2Coarctation (simple)6000100 0 0 110 0 0 80 0 0 350 0 0 3 +VSD591 (12.5)00501 (2.0)0 2 (4.0)90 0 0 20 0 0 1201 (0.8)0 2 (1.7)4 +DORV8001 (12.5)30 0 0 50 0 0 00 0 0 161 (6.3)0 1 (6.3)5 +AVSD22 (100.0)02 (100.0)21 (50.0)0 1 (50.0)00 0 0 10 0 0 53 (60.0)0 3 (60.0)6 +TGA600020 0 0 00 0 0 00 0 0 80 0 0 7 +SV800060 0 0 20 0 0 00 0 0 160 0 0 8 +Others900020 0 0 50 0 0 30 0 0 190 0 0 9Interrupt. of Ao (simple)100010 0 0 00 0 0 00 0 0 20 0 0 10 +VSD302 (6.7)02 (6.7)241 (4.2)0 1 (4.2)50 0 0 20 0 0 613 (4.9)0 3 (4.9)11 +DORV4000 10 0 0 00 0 0 00 0 0 50 0 0 12 +Truncus000 0 10 0 0 00 0 0 00 0 0 10 0 0 13 +TGA000 0 00 0 0 10 0 0 00 0 0 10 0 0 14 +Others200 0 91 (11.1)0 1 (11.1)40 0 0 00 0 0 151 (6.7)0 1 (6.7)15Vascular ring000 0 30 0 0 10 0 0 00 0 0 40 0 0 16PS00 0 0 100 0 0 221 (4.5)0 0 30 0 0 351 (2.9)0 0 17PAIVS or critical PS200 0 2 (10.0)570 0 0 550 0 1 (1.8)51 (20.0)0 1 (20.0)1371 (0.7)0 4 (2.9)18TAPVR10812 (11.1)0 15 (13.9)552 (4)0 2 (3.6)120 0 0 00 0 0 17514 (8)0 17 (10)19PAPVR ± ASD80 0 0 130 0 0 460 0 0 280 0 0 950 0 0 20ASD350 2 (5.7)0 650 0 0 6760 0 0 5450 0 2 (0.4)13210 2 (0.15)2 (0.2)21Cor triatriatum00 0 0 120 0 0 50 0 0 20 0 0 190 0 0 22AVSD (partial)00 0 0 180 0 0 570 0 0 161 (6.3)0 1 (6.3)911 (1.1)0 1 (1.1)23AVSD (complete)10 0 0 900 0 0 751 (1.3)0 1 (1.3)20 0 0 1681 (0.6)0 1 (0.6)24 +TOF or DORV20 0 0 130 0 0 231 (4.3)0 1 (4.3)00 0 0 381 (2.6)0 1 (2.6)25 +Others10 0 1 (100.0)40 0 1 (25.0)90 0 1 (11.1)00 0 0 140 0 3 (21.4)26VSD (subarterial)30 0 0 1220 0 0 1790 0 0 330 0 0 3370 0 0 27VSD (perimemb/muscular)120 0 0 8094 (0.5)0 5 (0.6)3840 0 1 (0.3)811 (1.2)0 1 (1.2)12865 (0.4)0 7 (0.5)28VSD + PS00 0 0 150 0 0 150 0 0 30 0 0 330 0 0 29DCRV ± VSD00 0 0 150 0 0 370 0 0 140 0 0 660 0 0 30Aneurysm of sinus valsalva00 0 0 00 0 0 20 0 0 331 (3.0)0 1 (3.0)351 (2.9)0 1 (2.9)31TOF80 0 0 2061 (0.5)0 2 (1.0)2352 (0.9)0 4 (1.7)400 0 1 (2.5)4893 (0.6)0 7 (1.4)32PA + VSD81 (12.5)0 2 (25.0)583 (5.2)0 3 (5.2)1002 (2.0)0 2 (2.0)90 0 0 1756 (3.4)0 7 (4.0)33DORV121 (8.3)0 1 (8.3)983 (3.1)0 3 (3.1)1110 0 0 80 0 0 2294 (1.7)0 4 (1.7)34TGA (simple)983 (3.1)0 4 (4.1)60 0 0 40 0 0 20 0 0 1103 (2.7)0 4 (3.6)35 +VSD311 (3.2)0 2 (6.5)181 (5.6)0 1 (5.6)70 0 0 20 0 0 582 (3.4)0 3 (5.2)36 VSD + PS10 0 0 110 0 0 130 0 1 (7.7)30 0 0 280 0 1 (3.6)37Corrected TGA10 1 (100.0)0 110 0 0 370 0 0 110 0 1 (9.1)600 1 (1.7)1 (1.7)38Truncus arteriosus60 0 0 212 (9.5)0 2 (9.5)140 0 0 10 0 0 422 (4.8)0 2 (4.8)39SV315 (16.1)0 9 (29.0)19310 (5.2)0 15 (7.8)2874 (1.4)0 6 (2.1)160 0 0 52719 (3.6)0 30 (5.7)40TA21 (50.0)0 2 (100.0)381 (2.6)1 (2.6)1 (2.6)450 0 0 40 0 0 892 (2.2)1 (1.1)3 (3.4)41HLHS387 (18.4)0 11 (28.9)1093 (2.8)0 9 (8.3)720 0 0 00 0 0 21910 (4.6)0 20 (9.1)42Aortic valve lesion40 0 0 210 0 2 (9.5)890 0 0 270 0 0 1410 0 2 (1.4)43Mitral valve lesion50 0 1 (20.0)381 (2.6)0 1 (2.6)621 (1.6)0 1 (1.6)110 0 0 1162 (1.7)0 3 (2.6)44Ebstein161 (6.3)0 3 (18.8)161 (6.3)0 1 (6.3)250 0 0 210 0 0 782 (2.6)0 4 (5.1)45Coronary disease20 0 0 210 0 0 90 0 0 171 (5.9)0 1 (5.9)491 (2.0)0 1 (2.0)46Others110 0 2 (18.2)293 (10.3)0 4 (13.8)471 (2.1)0 2 (4.3)110 0 0 984 (4.1)0 8 (8.2)47Redo VSD10 0 0 70 0 1 (14.3)90 0 0 50 0 0 220 0 1 (4.5)48 PS release00 0 0 120 0 0 572 (3.5)0 2 (3.5)200 0 0 892 (2.2)0 2 (2.2)49 RV-PA conduit replace20 0 0 50 0 0 600 0 0 350 0 0 1020 0 0 50 Others82 (25.0)0 2 (25.0)571 (1.8)0 2 (3.5)1172 (1.7)0 3 (2.6)691 (1.4)0 1 (1.4)2516 (2.4)0 8 (3.2)Total61339 (6.4)3 (0.5)62 (10.1)238840 (1.7)1 (0.04)60 (2.5)304217 (0.6)0 26 (0.9)11077 (0.6)0 11 (1.0)7150103 (1.4)4 (0.1)159 (2.2)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass, *PDA* patient ductus arteriosus, *VSD* ventircular septal defect, *DORV* double outlet right ventricle, *AVSD* atrioventricular septal defect, *TGA* transposition of great arteries, *SV* single ventricle, *Interupt. of Ao.* interruption of aorta, *PS* pulmonary stenosis, *PA-IVS* pulmonary atresia with intact ventricular septum, *TAPVR* total anomalous pulmonary venous return, *PAPVR* partial anomalous pulmonary venous return, *ASD* atrial septal defect, *TOF* tetralogy of Fallot, *DCRV* double-chambered right ventricle, *TA* tricuspid atresia, *HLHS* hypoplastic left heart syndrome, *RV-PA* right ventricle-pulmonary artery (2) CPB (−) (total; 2216)NeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1PDA4224 (0.9)08 (1.9)2112 (0.9)05 (2.4)3300020006686 (0.9)013 (1.9)2Coarctation (simple)130001500050002000350003 +VSD471 (2.1)02 (4.3)2300010000000711 (1.4)0 (0.0)2 (2.8)4 +DORV14000000000000000140005 +AVSD41 (25.0)01 (25.0)40001000000091 (11.1)01 (11.1)6 +TGA600010000000000070007 +SV12000300000000000150008 +Others300041 (25.0)01 (25.0)0000000071 (14.3)01 (14.3)9Interrupt. of Ao (simple)0000000000000000000010 +VSD271 (3.7)01 (3.7)000000000000271 (3.7)01 (3.7)11 +DORV7001 (14)2000000000009001 (11.1)12 +Truncus1000000000000000100013 +TGA2000000000000000200014 +Others81 (12.5)02 (25.0)10000000000091 (11.1)02 (22.2)15Vascular ring800012000200010002300016PS0000200020000000400017PAIVS or critical PS352 (5.7)04 (11.4)24001 (4.2)40000000632 (3.2)05 (7.9)18TAPVR2000200000000000400019PAPVR ± ASD0000000020000000200020ASD000000008000110001900021Cor triatriatum0000000000000000000022AVSD (partial)1000100000000000200023AVSD (complete)32001 (3.1)7400050000000111001 (0.9)24 +TOF or DORV200013000200000001700025 +Others72 (28.6)02 (28.6)10001000000092 (22.2)02 (22.2)26VSD (subarterial)300011000000000001400027VSD (perimemb/muscular)370001162 (1.7)02 (1.7)500030001612 (1.2)02 (1.2)28VSD + PS0000200000000000200029DCRV ± VSD0000100000001000200030Aneurysm of sinus valsalva11 (100.0)01 (100.0)11 (100.0)01 (100.0)0000000022 (100.0)02 (100.0)31TOF251 (4.0)01 (4.0)1261 (0.8)01 (0.8)1700020001702 (1.2)02 (1.2)32PA + VSD2100064000180002001 (50.0)105001 (1.0)33DORV351 (2.9)02 (5.7)551 (1.8)02 (3.6)70001000982 (2.0)04 (4.1)34TGA (simple)1000300000000000400035 +VSD4000200010001000800036 VSD + PS60008000000000001400037Corrected TGA700015000800000003000038Truncus arteriosus201 (5.0)01 (5.0)101 (10.0)01 (10.0)00000000302 (6.7)02 (6.7)39SV691 (1.4)01 (1.4)592 (3.4)04 (6.8)1600020001463 (2.1)05 (3.4)40TA161 (6.3)01 (6.3)2000050001000421 (2.4)01 (2.4)41HLHS781 (1.3)05 (6.4)92 (22.2)02 (22.2)70000000943 (3.2)07 (7.4)42Aortic valve lesion3000000020000000500043Mitral valve lesion0000000000000000000044Ebstein21 (50.0)01 (50.0)700020000000111 (9.1)01 (9.1)45Coronary disease1000100030000000500046Others11000181 (5.6)01 (5.6)35001 (2.9)8000721 (1.4)02 (2.8)47Redo VSD0000000010000000100048 PS release0000300040002000900049 RV-PA conduit replace0000000000000000000050 Others130002300024000300063000Total100620 (2.0)035 (3.5)94714 (1.5)021 (2.2)221001 (0.5)42001 (2.4)221634 (1.5)0 (0.00)58 (2.6)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass, *PDA* patient ductus arteriosus, *VSD* ventricular septal defect, *DORV* double outlet right ventricle, *AVSD* atrioventricular septal defect, *TGA* transposition of great arteries, *SV* single ventricle, *Interupt. of Ao.* interruption of aorta, *PS* pulmonary stenosis, *PA-IVS* pulmonary atresia with intact ventricular septum, *TAPVR* total anomalous pulmonary venous return, *PAPVR* partial anomalous pulmonary venous return, *ASD* atrial septal defect, *TOF* tetralogy of Fallot, *DCRV* double-chambered right ventricle, *TA* tricuspid atresia, *HLHS* hypoplastic left heart syndrome, *RV-PA* right ventricle-pulmonary artery (3) Main procedureNeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1SP shunt1825 (2.7)011 (6.0)3958 (2.0)012 (3.0)670005001 (20.0)64913 (2.0)024 (3.7)2PAB37511 (2.9)019 (5.1)2825 (1.8)09 (3.2)18000400067916 (2.4)028 (4.1)3Bidirectional Glenn or hemi-Fontan ± α15001 (6.7)2543 (1.2)05 (2.0)841 (1.2)01 (1.2)30003564 (1.1)07 (2.0)4Damus--Kaye--Stansel operation31 (33.3)0150406240000000775 (6.5)07 (9.1)5PA reconstruction/repair (including redo)12000724 (5.6)07 (9.7)1071 (0.9)02 (1.9)150002065 (2.4)09 (4.4)6RVOT reconstruction/repair222 (9.1)02 (9.1)1051 (1.0)01 (1.0)1631 (0.6)01 (0.6)220003124 (1.3)04 (1.3)7Rastelli procedure5000672 (3.0)02 (3.0)98000100001802 (1.1)02 (1.1)8Arterial switch procedure1295 (3.9)06 (4.7)272 (7.4)02 (7.4)800000001647 (4.3)08 (4.9)9Atrial switch procedure3000000010000000400010Double switch procedure000020001000010001300011Repair of anomalous origin of CA10009000400060002000012Closure of coronary AV fistula300010005000211 (4.8)01 (4.8)301 (3.3)01 (3.3)13Fontan/TCPC300060004174 (1.0)05 (1.2)242 (8.3)02 (8.3)4506 (1.3)07 (1.6)14Norwood procedure355 (14.3)09 (25.7)705 (7.1)011 (15.7)3000000010810 (9.3)020 (18.5)15Ventricular septation0000100000001000200016Left side AV valve repair (including Redo)200051000640001700013400017Left side AV valve replace (including Redo)2000161 (6.3)02 (12.5)401 (2.5)01 (2.5)15000732 (2.7)03 (4.1)18Right side AV valve repair (including Redo)82 (25.0)02 (25.0)210002500023001 (4.3)772 (2.6)03 (3.9)19Right side AV valve replace (including Redo)00006001 (16.7)20001400022001 (4.5)20Common AV valve repair (including Redo)21 (50.0)01 (50.0)191 (5.3)02 (10.5)281 (3.6)01 (3.6)3000523 (5.8)04 (7.7)21Common AV valve replace (including Redo)000020006001 (16.7)00008001 (12.5)22Repair of supra-aortic stenosis000010001900050002500023Repair of subaortic stenosis (including Redo)300090002900050004600024Aortic valve plasty ± VSD Closure600012001 (8.3)21000600045001 (2.2)25Aortic valve replacement00001000251 (4.0)01 (4.0)26000521 (1.9)01 (1.9)26AVR with annular enlargement000000001100010001200027Aortic root Replace (except Ross)00001000400060001100028Ross procedure0000300013000000016000Total81132 (3.9)0 (0.0)52 (6.4)148336 (2.4)061 (4.1)129610 (0.8)013 (1.0)2333 (1.3)05 (2.1)382381 (2.1)0131 (3.4)Values in parenthesis represent mortality %*SP* systemic-pulmonary, *PAB* pulmonary artery banding, *PA* pulmonary artery, *RVOT* right ventricular outflow tract, *CA* coronary artery, *AV* *fustula* arteriovenous fistula, *TCPC* total cavopulmonary connection, *AV valve* atrioventricular valve, *VSD* ventricular septal defect, *AVR* aortic valve replacement **Table 4** Acquired (total, (1) + (2) + (4) + (5) + (6) + (7) + isolated ope. for arrhythmia in (3); 40,039(1) Valvular heart disease (total; 21,758)ValveCasesOperation30-day mortalityHospital mortalityRedoMechanicalBioprosthesisRoss ProcedureRepairWith CABGHospitalAfter dischargeCases30-day mortalityHospital mortalityReplaceRepairReplaceRepairReplaceRepairHospitalAfter dischargeIsolatedA10,3792040799453402405221 (2.2)6 (1.8)5 (0.05)0294 (2.9)8 (2.4)39728 (7.1)036 (9.1)M47936978820321473559 (3.7)25 (0.8)0086 (5.4)35 (1.1)35413 (3.7)020 (5.6)T3067582413402 (0.8)002 (3.1)4 (1.7)47001 (2.1)P806210000004000A + MA144339299205924655 (3.8)067 (4.6)897 (7.9)010 (11.2)M2854160742A + TA4451053290114910 (2.2)019 (4.3)47002 (4.3)T3192421M + TM3369583902188430449 (1.5)3 (0.1)85 (2.5)2087 (3.4)1 (0.5)10 (4.8)T5663298A + M + TA97226168502610347 (4.8)2 (0.2)67 (6.9)746 (8.1)012 (16.2)M2003801391T5170950Others43122402032 (4.7)02 (4.7)14000Total21,758459512,770811,5993880476 (2.2)10 (0.05)669 (3.1)123461 (4.9)1 (0.1)91 (7.4)Number of redo cases is included in total case number of 21,758Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting, *A* aortic valve, *M* mitral valve, *T* tricuspid valve, *P* pulmonary valve (2) Ischemic heart disease (total, (A) + (B) + (C); 16,560)(*A*) *Isolated CABG* (*total*; (*a*)+(*b*); *15,333*)(a-1) on-pump arrest CABG (total; 3422)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft + SVGSVG onlyOthersCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD1031 (1.0)02 (1.9)261 (3.8)02 (7.7)61 (16.7)01 (16.7)100061225212VD5041 (0.2)02 (0.4)578 (14.0)08 (14.0)30000000844473303VD152313 (0.9)019 (1.2)1676 (3.6)08 (4.8)140002000661592480LMT78911 (1.4)020 (2.5)2209 (4.1)012 (5.5)50002000102872393Total291926 (0.9)043 (1.5)47024 (5.1)30 (6.4)281 (3.6)1 (3.6)50031329331724Kawasaki80000000100000006300Hemodialysis1772 (1.1)04 (2.3)272 (7.4)02 (7.4)300010006190120Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft, *LMT* includes LMT alone or LMT with other branch diseases (a-2) On-pump beating CABG (total; 2121)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft + SVGSVG onlyOthersUnclearCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD421 (2.4)02 (4.8)174 (23.5)04 (23.5)11001 (9.1)52 (40.0)02 (40.0)341030012VD2481 (0.4)02 (0.8)8413 (15.5)018 (21.4)400010005824928113VD86014 (1.6)0 (0.0)27 (3.1)19618 (9.2)022 (11.2)120000000909215700LMT4345 (1.2)1 (0.2)5 (1.2)19513 (6.7)0 (0.0)17 (8.7)1000021 (50.0)01 (50.0)875213102Total158421 (1.3)1 (0.1)36 (2.3)49248 (9.8)61 (12.4)3701 (2.7)83 (37.5)3 (37.5)269170114610Kawasaki100000000000000010000Hemodialysis1542 (1.3)04 (2.6)675 (7.5)08 (11.9)30002000141931801Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft, *LMT* includes LMT alone or LMT with other branch diseases (b) off-pump CABG (total; 9790)(The present section also includes cases of planned off-pump CABG in which, during surgery, the change is made to an on-pump CABG or on-pump beating-heart procedure)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft + SVGSVG onlyOthersCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD5732 (0.3)03 (0.5)733 (4.1)08 (11.0)341 (2.9)01 (2.9)9000570477202VD153313 (0.8)026 (1.7)1507 (4.7)010 (6.7)19000200062510245503VD394730 (0.8)050 (1.3)38313 (3.4)020 (5.2)12001 (8.3)10008403433702LMT24688 (0.3)1 (0.0)19 (0.8)55321 (3.8)025 (4.5)280005002 (40.0)8182168680Total852153 (0.6)1 (0.0)98 (1.2)115944 (3.8)63 (5.4)931 (1.1)2 (2.2)1702 (11.8)285366722652Kawasaki70001000000000006110Hemodialysis5817 (1.2)015 (2.6)797 (8.9)09 (11.4)70005000131511300Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft, *LMT* includes LMT alone or LMT with other branch diseases (c) Includes cases of conversion, during surgery, from off-pump CABG to on-pump CABG or on- pump beating-heart CABG (total; 171)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeA conversion to on-pump CABG arrest heart332 (6.1)02 (6.1)30000000000A conversion to on-pump beating-heart CABG1044 (3.8)05 (4.8)314 (12.9)04 (12.9)0000000Total1376 (4.4)07 (5.1)344 (11.8)4 (11.8)00000000Hemodialysis101 (10.0)01 (10.0)32 (66.7)2 (66.7)00000000Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting (*B*) *Operation for complications of MI* (*total; 1226*)ChronicAcuteConcomitant operationCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeCABGMVPMVRInfarctectomy or aneurysmectomy33610 (3.0)017 (5.1)295 (17.2)1 (3.4)7 (24.1)24711519VSP closure575 (8.8)1 (1.8)5 (8.8)22164 (29.0)3 (1.4)85 (38.5)7625Cardiac rupture213 (14.3)04 (19.0)17652 (29.5)1 (0.6)59 (33.5)2313Mitral regurgitation 1) Papillary muscle rupture90004310 (23.3)012 (27.9)20336 2) Ischemic28911 (3.8)026 (9.0)3011 (36.7)1 (3.3)13 (43.3)25422255Others82 (25.0)02 (25.0)71 (14.3)01 (14.3)601Total72031 (4.3)1 (0.1)54 (7.5)506143 (28.3)6 (1.2)177 (35.0)626343119Values in parenthesis represent mortality %Acute, within 2 weeks from the onset of myocardial infarction*MI* myocardial infarction, *CABG* coronary artery bypass grafting, *MVP* mitral valve repair, *MVR* mitral valve replacement, *VSP* ventricular septal perforation (*C*) *TMLR* (*total; 1*)Cases30-day mortalityHospital mortalityHospitalAfter dischargeIsolated1000With CABG0000Total1000*TMLR* transmyocardial laser revascularization (3) Operation for arrhythmia (total; 4000)Cases30-day mortalityHospital mortalityConcomitant operationIsolatedCongenitalValveIHDOthersMultiple combinationHospitalAfter discharge2 categories3 categoriesMaze376340 (1.1)2 (0.05)59 (1.6)64159333847918942128For WPW00000000000For ventricular tachyarrythmia431 (2.3)01 (2.3)311323850Others1942 (1.0)04 (2.1)1191395024333Total400043 (1.1)2 (0.05)64 (1.6)68179349055222145931Values in parenthesis represent mortality %. Except for 68 isolated cases, all remaining 3932 cases are doubly allocated, one for this subgroup and the other for the subgroup corresponding to the concomitant operations*WPW* Wolff--Parkinson--White syndrome, *IHD* ischemic heart disease (4) Operation for constrictive pericarditis (total; 198)CPB (+)CPB (−)Cases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospital96Total995 (5.1)07 (7.1)992 (2.0)04 (4.0)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass (5) Cardiac tumor (total; 634)Cases30-day mortalityHospital mortalityConcomitant operationHospitalAfter dischargeAVRMVRCABGOthersBenign tumor5505 (0.9)3 (0.5)6 (1.1)12133161 Cardiac myxoma4044 (1.0)3 (0.7)4 (1.0)982142 Papillary fibroelastoma6300032713 Rhabdomyoma10000000 Others821 (1.2)02 (2.4)0333Malignant tumor843 (3.6)1 (1.2)9 (10.7)03511 Primary521 (1.9)1 (1.9)6 (11.5)0332 Metastatic322 (6.3)03 (9.4)0029Values in parenthesis represent mortality %*AVR* aortic valve replacement, *MVR* mitral valve replacement, *CABG* coronary artery bypass grafting (6) HOCM and DCM (total; 240)Cases30-day mortalityHospital mortalityConcomitant operationHospitalAfter dischargeAVRMVRMVPCABGMyectomy1621 (0.6)01 (0.6)86272216Myotomy4001 (25.0)0110No-resection383 (7.9)05 (13.2)420142Volume reduction surgery of the left ventricle363 (8.3)05 (13.9)16195Total2407 (2.9)012 (5.0)91545623Values in parenthesis represent mortality %*HOCM* hypertrophic obstructive cardiomyopathy, *DCM* dilated cardiomyopathy, *AVR* aortic valve replacement, *MVR* mitral valve replacement, *MVP* mitral valve repair, *CABG* coronary artery bypass grafting (7) Other open-heart operation (total; 586)Cases30-day mortalityHospital mortalityHospitalAfter dischargeTotal58632 (5.5)045 (7.7)Values in parenthesis represent mortality % **Table 5** Thoracic aortic aneurysm (total; 15,758)(1) Dissection (total; 6787)Replaced siteStanford typeAcuteChronicConcomitant operationRedoABABCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityAVPAVRMVPMVRCABGCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1. Ascending Ao.2608186 (7.1)2 (0.1)217 (8.3)40 (0.0)01 (25.0)1863 (1.6)06 (3.2)80 (0.0)00 (0.0)216111178132512 (3.9)04 (7.8)2. Aortic Root19734 (17.3)035 (17.8)0000656 (9.2)07 (10.8)1000371856142385 (13.2)05 (13.2)3. Ascending Ao. + Arch1393108 (7.8)0124 (8.9)321 (3.1)02 (6.3)2826 (2.1)011 (3.9)1123 (2.7)04 (3.6)106623495914 (4.4)08 (8.8)4. Arch + descending Ao.251 (4.0)02 (8.0)61 (16.7)02 (33.3)314 (12.9)04 (12.9)564 (7.1)04 (7.1)00002176 (35.3)05 (29.4)5. Aortic Root + Asc. Ao. + Arch8612 (14.0)014 (16.3)2000331 (3.0)01 (3.0)1300022851015180006. Descending Ao.133 (23.1)03 (23.1)376 (16.2)05 (13.5)842 (2.4)03 (3.6)27012 (4.4)017 (6.3)00004411 (2.4)03 (7.3)7. Thoracoabdominal Ao.1000111 (9.1)03 (27.3)294 (13.8)04 (13.8)1459 (6.2)012 (8.3)00001475 (10.6)06 (12.8)8. Extra-anatomical bypass14202 (14.3)242 (8.3)03 (12.5)2000 (0.0)30000000031 (33.3)01 (33.3)9. Stent graft\*^a^1079 (8.4)07 (6.5)18117 (9.4)021 (11.6)139001 (0.7)5876 (1.0)112 (2.0)62003702 (2.9)03 (4.3) 1) TEVARl\*^b^487 (14.6)07 (14.6)17916 (8.9)020 (11.2)119001 (0.8)5566 (1.1)112 (2.2)62003702 (2.9)03 (4.3) 2) Open stent592 (3.4)0021 (50.0)01 (50.0)20001 (5.0)310012 (38.7)51001682 (2.9)03 (4.4)  a) With total arch\*^c^592 (3.4)0021 (50.0)01 (50.0)2000016000110021000  b) Without total arch\*^d^00000000000015000000001000 3) Unspecified0000000000000000000000000Total4444355 (8.0)2 (0.05)404 (9.1)29728 (9.4)037 (12.5)85126 (3.1)0 (0.0)37 (4.3)119534 (2.8)149 (4.1)387445271329437626 (6.9)035 (9.3)Values in parenthesis represent mortality %*Ao* aorta, *AVP* aortic valve repair, *AVR* aortic valve replacement, *MVP* mitral valve repair, *MVR* mitral valve replacement, *CABG* coronary artery bypass grafting, *TEVAR* thoracic endovascular aortic (aneurysm) repairAcute, within 2 weeks from the onset\*a = \*b + \*c + \*d + unspecified (2) Non-dissection (total; 8971)Replaced siteUnrupturedRupturedConcomitant operationRedoCPB (−)Cases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityAVPAVRMVPMVRCABGCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1. Ascending Ao.120125 (2.1)032 (2.7)627 (12.9)09 (14.5)408206739147957 (7.4)010 (10.5)20002. Aortic Root92816 (1.7)1 (0.1)24 (2.6)318 (30.8)08 (25.8)23263154249514513 (9.0)014 (9.7)10003. Ascending Ao. + Arch215144 (2.0)072 (3.3)17325 (14.8)037 (21.4)332012883271058 (7.6)010 (9.5)60004. Arch + descending Ao.1046 (5.8)09 (8.7)233 (34.3)05 (21.7)02017113 (27.3)04 (36.4)80005. Aortic root + Asc. Ao. + Arch1091 (0.9)02 (1.8)52 (50.0)02 (40.0)2480516203 (15.0)03 (15.0)20006. Descending Ao.34312 (3.5)018 (5.2)8416 (19.7)018 (21.4)00004333 (9.1)06 (18.2)262 (7.7)02 (7.7)7. Thoracoabdominal Ao.37217 (4.6)1 (0.3)28 (7.5)529 (24.3)015 (28.8)00001421 (2.4)03 (7.1)110008. Extra-anatomical bypass35001 (2.9)20 (0.0)0010001100020 (0.0)009. Stent graft\*^a^292843 (1.5)1 (0.03)73 (2.5)36839 (12.9)3 (0.8)55 (14.9)7710251226 (4.9)1 (0.8)7 (5.7)107919 (1.8)3 (0.3)28 (2.6) 1) TEVAR\*^b^277437 (1.3)1 (0.04)66 (2.4)35838 (13.7)3 (0.8)53 (14.8)310051185 (4.2)1 (0.8)6 (5.1)105919 (1.8)3 (0.3)28 (2.6) 2) Open stent1546 (3.9)07 (4.5)101 (10.0)02 (20.0)46102041 (25.0)01 (25.0)20000  a) With total arch\*^c^42000000001004200020000  b) Without total arch\*^d^1126 (5.4)07 (6.3)101 (10.0)02 (20.0)45101621 (50.0)01 (50.0)0000  3) Unspecified00000000000000000000Total8171164 (2.0)3 (0.04)259 (3.2)800109 (13.6)3 (0.4)149 (22.2)33717411557361357444 (7.7)1 (0.2)57 (9.9)113721 (3.0)3 (0.3)30 (2.6)Values in parenthesis represent mortality %*Ao* aorta, *AVP* aortic valve repair, *AVR* aortic valve replacement, *MVP* mitral valve repair, *MVR* mitral valve replacement, *CABG* coronary artery bypass grafting, *TEVAR* thoracic endovascular aortic (aneurysm) repair\*a = \*b + \*c + \*d + unspecified **Table 6** Pulmonary thromboembolism (total; 176)Cases30-day mortalityHospital mortalityHospitalAfter dischargeAcute11416 (14.0)017 (14.9)Chronic623 (4.8)04 (6.5)Total17619 (10.8)021 (11.9)Values in parenthesis represent mortality % **Table 7** Assisted circulation (total; 1713)SitesVADHeart--lung assistDeviceResultsMethodResultsCentrifugalVASOthersNot weanedWeanedPCPSOthersNot weanedWeanedOn goingDeathTransplantAliveDeathsTransplantDeathsTransplantDeathsAlivePost cardiotomy Left3847830 (61.2)038 (19.0)0 Right000000000 Biventricle  Left13003 (75.0)010049969274 (54.9)085 (17.0)209  Right400Congestive heart failure Left50419211238 (20.8)7169 (9.9)0 Right210100200 Biventricle  Left5223514 (46.7)083 (10.3)068529360 (52.6)0105 (15.3)249  Right18111Respiratory failure1062246 (43.4)016 (15.1)66Total1188210312685 (28.1)73020 (6.6)01290120680 (52.7)2206 (16.0)524Values in parenthesis represent mortality %*VAD* ventricular assist devise, *VAS* ventricular assist system, *PCPS* percutaneous cardiopulmonary support **Table 8** Heart transplantation (total; 37)Cases30-day mortalityHospital mortalityHospitalAfter dischargeHeart transplantation36000Heart and lung transplantation1000Total37000Values in parenthesis represent mortality % **Table 9** Pacemaker + ICD (total; 4202)PacemakerICDVA-VCRTCRTDICDInitial508183678168210Exchange4559013090184Unclear00000Total9632737108258394*ICD* implantable cardioverter-defibrillator, *CRTD* cardiac resynchronization therapy devise with incorporated ICD devise

In 2013, 7150 open-heart operations for congenital heart disease were performed with overall hospital mortality of 2.2 % (Table [3](#Tab3){ref-type="table"}). The number of operations for congenital heart disease was quite steady throughout these 10 years (maximum 7386 cases in 2006), while overall hospital mortality decreased gradually from that of 3.7 % in 2003. In detail, the most common disease was atrial septal defect (1321 cases); however, its number deceased to 71.7 % of that in 2003, which might be due to the recent development of catheter closure of atrial septal defect in Japan. Hospital mortality for complex congenital heart disease improved dramatically in the last 10 years such as interrupted aortic arch with ventricular septal defect (6.7 % in 2003 to 4.9 % in 2013), complete atrio-septal defect (5.7--0.6 %), tetralogy of Fallot (2.6--1.4 %), transposition of the great arteries with and without ventricular septal defect (10.5--5.2 % and 7.5--3.6 %, respectively), single ventricle (7.1--5.7 %), and hypoplastic left heart syndrome (27.2--9.1 %). Right heart bypass surgery is now commonly performed (356 bidirectional Glenn procedures excluding 77 Damus--Kaye--Stansel procedures and 450 Fontan type procedures including total cavo-pulmonary connection) with acceptable hospital mortality (2.0 and 1.6 %). Norwood type I procedure was performed in 108 cases with relatively low hospital mortality rate of 18.5 %.

As previously mentioned, the number of operations for valvular heart disease increased by 83.4 % in the last 10 years, and the hospital mortality associated with primary single valve placement was 2.2 and 3.7 % for the aortic and the mitral position, while that for primary mitral valve repair was 0.8 % (Table [4](#Tab6){ref-type="table"} (1)). However, hospital mortality rate for redo valve surgery were still high, and was 9.1 and 5.6 % for aortic and mitral procedure, respectively. Finally, overall hospital mortality did not show significant improvement during the last 10 years (3.7 % in 2003 and 3.1 % in 2013), which might be partially due to the recent progression of age of the patients. Repair of the valve became popular procedure (436 cases in the aortic, 6231 cases in the mitral, and 4910 cases in the tricuspid), and mitral valve repair constituted 28.6 % of all valvular heart disease operation and 55.5 % of all mitral valve procedure (10,577 procedures), which are similar to those of the last 5 years and increased compared with those of 2003 (21.3 and 38.7 %, respectively). Aortic and mitral valve replacement with bioprosthesis were performed in 10,000 cases and 2580 cases, respectively, with the number consistently increasing in the aortic position. The ratio of prostheses changed dramatically during the last 10 years and the usage of bioprosthesis is 78.1 % at the aortic position (38.2 % in 2003) and 41.9 % at the mitral position (23.4 % in 2003). CABG as a concomitant procedure performed in 17.8 % of operations for all valvular heart disease (12.7 % in 2003).

Isolated CABG was performed in 15,333 cases which were only 72.9 % of that of 10 years ago (2003) (Table [4](#Tab7){ref-type="table"} (2)). Among these 15,333 cases, off-pump CABG was intended in 9790 cases (63.8 %) with a success rate of 98.3 %; so final success rate of off-pump CABG was 62.7 %. The percentage of intended off-pump CABG was 55.2 % in 2003, and was increased to 60.3 % in 2004, then was kept over 60 % until now. In 15,333 isolated CABG patients, 96.1 % of them received at least one arterial graft, while, all arterial graft CABG was performed in only 23.4 % of them.

The operative and hospital mortality rates associated with primary elective CABG procedures in 13,024 cases were 1.0 and 1.7 %, respectively. Similar data analysis of CABG including primary/redo and elective/emergency data was begun in 2003, and the operative and hospital mortality rates associated with primary elective CABG procedures in 2003 were 1.0 and 1.5 %, respectively; so operative results of primary CABG has been stable. However, hospital mortality of primary emergency CABG in 2121 cases was 5.5 %, which has been improved compared with 9.7 % of hospital mortality rate in 2003. In comparison with data in 2003, the results of conversion improved both conversion rate (3.1--1.7 %) and hospital mortality (8.5--6.4 %).

A total of 1226 patients underwent surgery for complications of myocardial infarction, including 414 operations for a left ventricular aneurysm or ventricular septal perforation or cardiac rupture and 298 operations for ischemic mitral regurgitation.

Operations for arrhythmia were performed mainly as a concomitant procedure in 4000 cases with satisfactory mortality (1.6 % hospital mortality) including 3763 MAZE procedures. MAZE procedure has become quite popular procedure when compared with that in 2003 (1472 cases).

Operations for thoracic aortic dissection were performed in 6787 cases (Table [5](#Tab18){ref-type="table"}). For 4444 Stanford type A acute aortic dissections, hospital mortality was 9.1 %, which was slightly improved compared to that in 2012 (10.6 %) and better than that in 2003 (14.5 %). Operations for a non-dissected thoracic aneurysm were carried out in 8171 cases, with overall hospital mortality of 4.5 %, which was better than that in 2012 (5.4 %). The hospital mortality associated with un-ruptured aneurysm was 2.2 %, and that of ruptured aneurysm was 22.2 %, which remains markedly high.

The number of stent graft procedures remarkably increased recently. A total of 1014 patients with aortic dissection underwent stent graft placement: thoracic endovascular aortic repair (TEVAR) in 902 cases and open stent grafting in 112 cases. The number of TEVAR for type B chronic aortic dissections increased from 77 cases in 2003 to 556 cases in 2013. The hospital mortality rates associated with TEVAR for type B aortic dissection were 11.2 % in acute cases and 2.2 % for chronic cases, respectively.

A total of 3296 patients with non-dissected aortic aneurysm underwent stent graft placement with a dramatic increase compared with that in 2003 (399 cases); TEVAR in 3132 cases (42 % increase compared with that in 2012) and open stent grafting in 164 cases (27.4 % decrease compared with that in 2012). The hospital mortality rates for TEVAR were 2.4 and 14.8 % for non-ruptured and ruptured aneurysm, respectively.

In summary, the total cardiovascular operations increased during 2013 by 3525 cases. With steadily improving results in almost all categories compared with those in 2012.

(B) General thoracic surgery {#Sec4}
----------------------------

The total number of operations reported in 2013 in general thoracic surgery has reached 75,306, which means increase of 2559 cases compared with the number of operations in 2012 (Fig. [2](#Fig2){ref-type="fig"} Table [10](#Tab24){ref-type="table"}).**Table 10** Total entry cases of general thoracic surgery during 2013Cases%Benign pulmonary tumor9481.3Primary lung cancer37,00849.1Other primary malignant pulmonary tumor3620.5Metastatic pulmonary tumor782910.4Tracheal tumor850.1Mesothelioma4390.6Chest wall tumor6920.9Mediastinal tumor47806.3Thymectomy for MG without thymoma2530.3Inflammatory pulmonary disease34454.6Empyema23683.1Bullous disease excluding pneumothorax5660.8Pneumothorax14,61219.4Chest wall deformity4030.5Diapharagmatic hernia including traumatic1010.1Chest trauma excluding diaphragmatic hernia4340.6Lung transplantation610.1Others9201.2Total75,306100.0 Fig. 2General thoracic surgery

Figure [2](#Fig2){ref-type="fig"} shows the development of thoracic surgery in Japan over 27 years. Data for individual categories are summarized in table through [10](#Tab24){ref-type="table"} to [34](#Tab48){ref-type="table"}. The number of operations for primary lung cancer in 2013 was 37,008, showing the steady increase (31,301, 2009; 32,801, 2010; 33,878, 2011; 35,667, 2012). Surgery for lung cancer consists of 49.1 % of all the general thoracic surgery. Among lung cancer subtypes, adenocarcinoma comprises an overwhelming percentage of 69.1 % of the total lung cancer surgery, followed by squamous cell carcinoma of 19.9 %. Limited resection by wedge resection or segmentectomy was performed in 8771 lung cancer patients, which is 23.7 % of the entire cases. Lobectomy was performed in 27,469 patients, which is 74.2 % of the entire cases. Sleeve lobectomy was done in 449 patients. Pneumonectomy was done in 559 patients which is only 1.5 % of the entire cases. VATS (video assisted thoracic surgery) procedure is performed in 70.8 % among the total lung cancer surgeries. VATS procedure was adopted in 4270 patients (86.2 %) in wedge resection, 2800 patients (73.4 %) in segmentectomy, 18,925 patients (68.9 %) in lobectomy, and 82 patients (14.7 %) in pneumonectomy. There were 123 patients who died within 30 days after lung cancer surgery (30-day mortality rate; 0.33 %), and 224 patients died without discharge (hospital mortality rate; 0.60 %). 30-day mortality rate in regard to procedures is 0.21 % in segmentectomy, 0.34 % in lobectomy, and 1.97 % in pneumonectomy (Table [12](#Tab26){ref-type="table"}).**Table 11**1. Benign pulmonary tumorCases30 day mortalityHospital mortalityBy VATSHospitalAfter dischargeHamartoma475000409Sclerosing hemangioma9500077Papilloma1700013Mucous gland adenoma bronchial70005Fibroma6000055Lipoma120009Neurogenic tumor90006Clear cell tumor50004Leiomyoma120009Chondroma30002Inflamatory myofibroblastic tumor10001Pseudolymphoma3000021Histiocytosis90009Teratoma30001Others2101 (0.5)01 (0.5)168Total9481 (0.1)01 (0.1)789Values in parenthesis represent mortality % **Table 12**2. Primary malignant pulmonary tumorCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge2. Primary malignant pulmonary tumor37,370113 (0.3)11 (0.03)227 (0.6)Lung cancer37,008112 (0.3)11 (0.03)225 (0.6)26,213 Adenocarcinoma25,55554 (0.2)4 (0.02)97 (0.4) Squamous cell carcinoma736541 (0.6)6 (0.08)89 (1.2) Large cell carcinoma9086 (0.7)110 (1.1) (*LCNEC*)*5173* (*0.6*)*16* (*1.2*) Small cell carcinoma5773 (0.5)05 (0.9) Adenosquamous carcinoma5861 (0.2)07 (1.2) Carcinoma with pleomorphic, sarcomatoid or sarcomatous elements4965 (1.0)011 (2.2) Carcinoid248000 Carcinomas of salivary-gland type45000 Unclassified65000 Multiple lung cancer10151 (0.1)03 (0.3) Others1481 (0.7)03 (2.0) Wedge resection49548 (0.2)113 (0.3)4270 Segmental excision38178 (0.2)015 (0.4)2800 (*Sleeve segmental excision*)*130003* Lobectomy27,46984 (0.3)9 (0.03)173 (0.6)18,925 (*Sleeve lobectomy*)*4494* (*0.9*)*1* (*0.2*)*5* (*1.1*)*54* Pneumonectomy55910 (1.8)120 (3.6)82 (*Sleeve pneumonectomy*)*100001* Other bronchoplasty60000 Pleuropneumonectomy60000Others2152 (0.9)03 (1.4)136Sarcoma28001 (3.6)AAH165000Others169001 (0.6)Values in parenthesis represent mortality % **Table 13** Details of lung cancer operationCasesc-Stage (TNM) Ia21,482 Ib7419 IIa2939 IIb1814 IIIa2587 IIIb233 IV400 NA136 Total37,010Sex Male22,996 Female14,007 NA7 Total37,010Cause of death Cardiovascular17 Pneumonia43 Pyothorax8 Bronchopleural fistula15 Respiratory failure18 Pulmonary embolism2 Interstitial pneumonia84 Brain infarction or bleeding8 Others37 Unknown5 Total237p-Stage 0 (pCR)222 Ia18,516 Ib7777 IIa3057 IIb2027 IIIa3905 IIIb263 IV979 NA264 Total37,010Age \<205 20--2926 30--39249 40--491030 50--593699 60--6912,589 70--7914,981 80--894334 ≥9088 NA9 Total37,010 **Table 14**3. Metastatic pulmonary tumorCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge3. Metastatic pulmonary tumor78297 (0.1)1 (0.01)16 (0.2)6323 Colorectal3898408 (0.2)3203 Hepatobiliary/pancreatic375001 (0.3)313 Uterine391000322 Mammary456001 (0.2)381 Ovarian7200059 Testicular5500041 Renal6081 (0.2)01 (0.2)515 Skeletal163000113 Soft tissue280000209 Otorhinolaryngological424000324 Pulmonary3821 (0.3)1 (0.3)2 (0.5)248 Others7251 (0.1)03 (0.4)595Values in parenthesis represent mortality % **Table 15**4. Tracheal tumorCases30 day mortalityHospital mortalityHospitalAfter discharge4. Tracheal tumor851 (1.2)01 (1.2)(A) Primary malignant tumor (histological classification) Squamous cell carcinoma9000 Adenoid cystic carcinoma15000 Mucoepidermoid carcinoma1000 Others4000 Total29000(B) Metastatic/invasive malignant tumor\
  e.g. invasion of thyroid cancer35000(C) Benign tracheal tumor (histological classification) Papilloma1000 Adenoma0000 Neurofibroma2000 Chondroma1000 Leiomyoma0000 Others171 (5.9)01 (5.9) Histology unknown0000 Total211 (4.8)01 (4.8)Operation Sleeve resection with reconstruction27000 Wedge with simple closure12000 Wedge with patch closure0000 Total laryngectomy with tracheostomy5000 Others411 (2.4)01 (2.4) Unknown0000 Total851 (1.2)01 (1.2)Values in parenthesis represent mortality % **Table 16**5. Tumor of pleural originCases30 day mortalityHospital mortalityHospitalAfter dischargeHistological classification Solitary fibrous tumor147001 (0.7) Diffuse malignant pleural mesothelioma2184 (1.8)011 (5.0) Localized malignant pleural mesothelioma18000 Others56001 (1.8) Total4394 (0.9)013 (3.0)Operative procedure Extrapleural pneumonectomy1194 (3.4)010 (8.4) Total pleurectomy42001 (2.4) Total parietal pleurectomy0000 Partial pleurectomy0000 Exploratory thoracotomy0000 Others57000 Total2184 (1.8)011 (5.0)Values in parenthesis represent mortality % **Table 17**6. Chest wall tumorCases30 day mortalityHospital mortalityBy VATSHospitalAfter dischargePrimary malignant tumor13300020Metastatic malignant tumor21300041Benign tumor346000211Total692000272 **Table 18**7. Mediastinal tumorCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge7. Mediastinal tumor47805 (0.1)09 (0.2)2624 Thymoma\*19042 (0.1)04 (0.2)765 Thymic cancer2791 (0.4)01 (0.4)69 Thymus carcinoid470009 Germ cell tumor243001 (0.4)87  *Benign16100077*  *Malignant82001* (*1.2*)*10* Neurogenic tumor513000434 Congenital cyst974000828 Goiter8500021 Lymphatic tumor192001 (0.5)101 Excision of pleural recurrence of thymoma872 (2.3)0047 Others456002 (0.4)263Values in parenthesis represent mortality %\* Includes those with myasthenia gravis **Table 19**8. Thymectomy for myasthenia gravisCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge8. Thymectomy for myasthenia gravis524001 (0.2)176With thymoma271001 (0.4)85Values in parenthesis represent mortality % **Table 20**9. Operation for non-neoplasmic disease(A) Inflammatory pulmonary diseaseCases30 day mortalityHospital mortalityHospitalAfter discharge9. Operation for non-neoplasmic disease22,84889 (0.4)7 (0.03)160 (0.7)Cases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge(A) Inflammatory pulmonary disease34454 (0.1)2 (0.1)11 (0.3)2682 Tuberculous infection991 (1.0)01 (1.0)70 Mycobacterial infection576000444 Fungal infection4473 (0.7)1 (0.2)6 (1.3)260 Bronchiectasis107001 (0.9)65  Tubeculous nodule268000227  Inflammatory pseudo tumor1338002 (0.1)1129  Interpulmonary lymph node158000147 Others45201 (0.2)1 (0.2)340Values in parenthesis represent mortality % **Table 21**9. Operation for non-neoplasmic disease(B) EmpyemaCases30 day mortalityHospital mortalityBy VATSHospitalAfter dischargeAcute empyema182725 (1.4)049 (2.7)1222 With fistula40316 (4.0)028 (6.9)126 Without fistula14099 (0.6)020 (1.4)1085 Unknown15001 (6.7)11Chronic empyema5417 (1.3)1 (0.2)21 (3.9)148 With fistula2874 (1.4)1 (0.3)13 (4.5)38 Without fistula2473 (1.2)08 (3.2)104 Unknown70006Total236832 (1.4)1 (0.04)70 (3.0)1370Values in parenthesis represent mortality % **Table 22**9. Operation for non-neoplasmic disease(C) Descending necrotizing mediastinitisCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge(C) Descending necrotizing mediastinitis981 (1.0)01 (1.0)59Values in parenthesis represent mortality % **Table 23**9. Operation for non-neoplasmic disease(D) Bullous diseaseCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge(D) Bullous disease5662 (0.4)02 (0.4)447 Emphysematous bulla4331 (0.2)01 (0.2)356 Bronchogenic cyst5700048 Emphysema with LVRS2400020 Others521 (1.9)0123Values in parenthesis represent mortality %*LVRS* lung volume reduction surgery **Table 24**9. Operation for non-neoplasmic disease(E) PneumothoraxCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge(E) Pneumothorax14,61229 (0.2)2 (0.01)49 (0.3)13,961*Spontaneous pneumothorax* Operative procedure  Bullectomy30490002912  Bullectomy with additional procedure83942 (0.02)1 (0.01)3 (0.04)8271  Coverage with artificial material80082 (0.02)1 (0.01)3 (0.04)7894  Parietal pleurectomy4500045  Coverage and parietal pleurectomy 4600043  Others295000289 Others4221 (0.2)01 (0.2)377 Unknown1500015 Total11,8803 (0.03)1 (0.01)4 (0.03)11,575*Secondary pneumothorax* Associated disease  COPD215115 (0.7)1 (0.05)22 (1.0)1899  Tumorous disease794 (5.1)08 (10.1)66  Catamenial150000146  LAM3100030  Others (excluding pneumothorax by trauma)3087 (2.3)015 (4.9)237  Unknown030 Operative procedure  Bullectomy3701 (0.3)05 (1.4)321  Bullectomy with additional procedure201816 (0.8)027 (1.3)1796   Coverage with artificial material185313 (0.7)024 (1.3)1659   Parietal pleurectomy1500012   Coverage and parietal pleurectomy212 (9.5)02 (9.5)15   Others1291 (0.8)01 (0.8)110  Others3409 (2.6)1 (0.3)13 (3.8)268  Unknown40001  Total273226 (1.0)1 (0.04)45 (1.6)2386Values in parenthesis represent mortality % **Table 25**9. Operation for non-neoplasmic disease(F) Chest wall deformityCases30 day mortalityHospital mortalityHospitalAfter discharge(F) Chest wall deformity403000 Funnel chest383000 Others20000 **Table 26**9. Operation for non-neoplasmic disease(G) Diaphragmatic herniaCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge(G) Diaphragmatic hernia1012 (2.0)03 (3.0)33 Congenital432 (4.7)03 (7.0)11 Traumatic3400010 Others2400012Values in parenthesis represent mortality % **Table 27**9. Operation for non-neoplasmic disease(H) Chest traumaCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge(H) Chest trauma43416 (3.7)1 (0.2)16 (3.7)171Values in parenthesis represent mortality % **Table 28**9. Operation for non-neoplasmic disease(I) Other respiratory surgeryCases30 day mortalityHospital mortalityBy VATSHospitalAfter discharge(I) Other respiratory surgery8223 (0.4)1 (0.1)8 (1.0)500 Arteriovenous malformation1031 (1.0)01 (1.0)94 Pulmonary sequestration117001 (0.9)84 Others6022 (0.3)1 (0.2)6 (1.0)322Values in parenthesis represent mortality % **Table 29**10. Lung transplantationCases30 day mortalityHospital mortalityHospitalAfter dischargeSingle lung transplantation from brain dead donor17000Bilateral lung transplantation from brain dead donor24001 (4.2)Lung transplantation from living donor20001 (5.0)Total of lung transplantation61002 (3.3)Donor of living donor lung transplantation31000Values in parenthesis represent mortality % **Table 30**11. Video-assisted thoracic surgeryCases30 day mortalityHospital mortalityHospitalAfter discharge11. Video-assisted thoracic surgery58,46684 (0.1)9 (0.02)135 (0.2)Values in parenthesis represent mortality %(Including Thoracic sympathectomy 160) **Table 31**12. TracheobronchoplastyCases30 day mortalityHospital mortalityHospitalAfter discharge12. Tracheobronchoplasty5642 (1.2)04 (0.7)Trachea1021 (1.0)02 (2.0) Sleeve resection with reconstruction53000 Wedge with simple closure32000 Wedge with patch closure1000 Total laryngectomy with tracheostomy4001 (25.0) Others121 (8.3)01 (8.3)Carinal reconstruction5001 (20.0)Sleeve pneumonectomy12000Sleeve lobectomy3881 (0.3)01 (0.3)Sleeve segmental excision15000Bronchoplasty without lung resection13000Others29000Values in parenthesis represent mortality % **Table 32**13. Pediatric surgeryCases30 day mortalityHospital mortalityHospitalAfter discharge13. Pediatric surgery3292 (0.6)04 (1.2)Values in parenthesis represent mortality % **Table 33**14. Combined resection of neighboring organ(s)Cases30 day mortalityHospital mortalityHospitalAfter discharge14. Combined resection of neighboring organ(s)15817 (1.4)3 (0.2)19 (1.2)(A) Primary lung cancer (organ resected) Aorta16000 Superior vena cava40000 Brachiocephalic vein12000 Pericardium1772 (1.1)03 (1.7) Pulmonary artery2271 (0.4)01 (0.4) Left atrium45001 (2.2) Diaphragm981 (1.0)01 (1.0) Chest wall (including ribs)5001 (0.2)09 (1.8) Vertebra31003 (9.7) Esophagus12000 Total11585 (0.4)018 (1.6)(B) Mediastinal tumor (organ resected) Aorta3000 Superior vena cava69001 (1.4) Brachiocephalic vein931 (1.1)01 (1.1) Pericardium2671 (0.4)02 (0.7) Pulmonary artery9000 Left atrium2000 Diaphragm16000 Chest wall (including ribs)20000 Vertebra7000 Esophagus1000 Lung2771 (0.4)01 (0.4) Total7643 (0.4)05 (0.7)Values in parenthesis represent mortality % **Table 34**15. Operation of lung cancer invading the chest wall of the apexCases30 day mortalityHospital mortalityHospitalAfter discharge15. Operation of lung cancer invading the chest wall of the apex98001 (0.01)Values in parenthesis represent mortality %Includes tumors invading the anterior apical chest wall and posterior apical chest wall (superior sulcus tumor, so called Pancoast type)

Interstitial pneumonia was the leading cause of death after lung cancer surgery, followed by pneumonia, respiratory failure, cardiovascular event, and bronchopleural fistula (Table [13](#Tab27){ref-type="table"}).

7829 patients with metastatic pulmonary tumor were operated in 2013 with steady increase similarly to lung cancer surgery (6248, 2009; 6748, 2010; 7210, 2011; 7403, 2012). VATS was adopted in 6323 cases, which comprises 80.8 % of the entire cases. Colo-rectal cancer was by far the leading primary malignancy indicated for resection of metastatic tumors, which comprises 49.8 % of the entire cases (Table [14](#Tab28){ref-type="table"}).

85 tracheal tumors were operated in 2013. Adenoid cystic carcinoma and squamous cell carcinoma were frequent primary tracheal tumors (Table [15](#Tab29){ref-type="table"}).

439 tumors of pleural origin were operated in 2013. Diffuse malignant pleural mesothelioma was the most frequent histology. Extrapleural pneumonectomy was the most frequently chosen operative method (119 cases) with a hospital death of 8.4 % (Table [16](#Tab30){ref-type="table"}).

692 chest wall tumors were resected in 2013 (Table [17](#Tab31){ref-type="table"}).

4780 mediastinal tumors were operated in 2013. There were 2230 thymic epithelial tumors (1904 thymomas, 279 thymic carcinomas, and 47 thymic neuroendocrine carcinoma including carcinoid), followed by 974 congenital cysts, 513 neurogenic tumors, and 243 germ cell tumors. 2624 cases (54.9 %) were resected by VATS (Table [18](#Tab32){ref-type="table"}).

Thymectomy for myasthenia gravis was done in 524 patients, and 271 patients were associated with thymoma, 253 patients were not associated with thymoma. VATS was adopted in 176 cases, which comprises 33.6 % of the entire cases (Table [19](#Tab33){ref-type="table"}).

Lung resection for inflammatory lung diseases were done in 3, 445 patients in 2013. Inflammatory pseudotumor comprised 38.8 % of the entire cases, followed by atypical mycobacterium infection (16.7 %) and fungal infections (13.0 %) (Table [20](#Tab34){ref-type="table"}).

2368 operations for empyema were reported in 2013. There were 1827 patients (77.2 %) with acute empyema and 541 patients with chronic empyema. Bronchopleural fistura was associated in 403 patients (22.1 %) with acute empyema and 287 patients (53.0 %) with chronic empyema. It should be noted that hospital mortality was as high as 10.9 % in patients of acute empyema with fistura (Table [21](#Tab35){ref-type="table"}).

14,612 operations for pneumothorax were reported in 2013. 13,961 operations (95.5 %) were performed by VATS (Table [24](#Tab38){ref-type="table"}).

61 lung transplantations were reported in 2013. Brain-dead donor lung transplantation and living-related donor lung transplantation were done in 41 recipients and 20 recipients, respectively. The number of lung transplantation is still small compared to those in North America and European countries because of shortage of donors (Table [29](#Tab43){ref-type="table"}).

(C) Esophageal surgery {#Sec5}
----------------------

During 2013 alone, a total of 17,656 patients with esophageal diseases were registered from 559 institutions (response rate 96.9 %) which affiliated to the Japanese Association for Thoracic Surgery and/or to the Japan Esophageal Society (Table [1](#Tab1){ref-type="table"}). Among these institutions, those where 20 or more patients underwent esophageal surgeries within the year of 2013 were 186 institutions (33.3 %), which shows no definite shift of esophageal operations to high volume institutions when compared to the data of 2012 (33.2 %) (Table [35](#Tab49){ref-type="table"}). Of 7562 patients with a benign esophageal disease, 1300 (17.2 %) patients underwent surgery, and 761 (10.1 %) patients underwent endoscopic resection, while 5501 (72.7 %) patients did not undergo any surgical treatment (Table [36](#Tab50){ref-type="table"}). Of 10,094 patients with a malignant esophageal tumor, 7677 (76.1 %) patients underwent resection, esophagectomy for 5824 (57.7 %) and endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for 1853 (18.4 %), while 2417 (23.9 %) patients did not undergo any resection (Tables [37](#Tab51){ref-type="table"}, [38](#Tab52){ref-type="table"}). The increase of registered patients with endoscopic resection and nonsurgically treated benign esophageal diseases is obvious during 2012 and 2013. The patients registered, particularly those undergoing ESD or EMR and nonsurgical therapy for a malignant esophageal disease, have been increasing since 1990 (Fig. [3](#Fig3){ref-type="fig"}).**Table 35**Distribution of number of esophageal operations in 2013 in each institutionEsophageal surgeryNumber of operations in 2013Benign esophageal diseasesMalignant esophageal diseaseBenign + malignant*0*268116841--4196108965--951698410--192310410920--298475630--396333540--4921926≧5056369Total559559559 **Table 36**Benign esophageal diseasesOperation (+)Endoscopic resectionOperation (−)TotalNumber of patients30-day mortalityHospital mortalityTotalOpenT/L\*3Open SurgeryT/L\*3TotalOpen surgeryT/L\*3TotalHospitalAfter dischargeTotalHospitalAfter discharge1. Achalasia322203119000000000313532. Benign tumor9057330002 (6.1)02 (6.1)3 (3.3)1 (1.8)2 (6.1)28336409 (1) Leiomyoma6036240001 (4.2)01 (4.2)1 (1.7)01 (4.2)1332105 (2) Cyst541000000000106 (3) Others251780001 (12.5)01 (12.5)2 (8.0)1 (5.9)1 (12.5)2684297 (4) Not specified0000000000001013. Diverticulum3025500000000045754. Hiatal hernia5093901191 (0.3)1 (0.3)00006 (1.2)5 (1.3)1 (0.8)194824575. Spontaneous rupture of the esophagus112100122 (2.0)2 (2.0)00005 (4.5)5 (5.0)0131256. Esophago-tracheal fistula161601 (6.3)1 (6.3)00001 (6.3)1 (6.3)05217. Congenital esophageal atresia484260000001 (2.1)1 (2.4)03518. Congenital esophageal stenosis10910000000005159. Corrosive stricture of the esophagus87100000000061410. Esophagitis, esophageal ulcer2823500000000041143911. Esophageal varices626114 (6.6)4 (6.6)00006 (9.7)6 (9.8)028602922 (1) Laparotomy1514102 (14.3)00003 (20.0)3 (21.4)015 (2) Sclerotherapy00000040728369012. Others655693 (5.4)2 (3.6)00007 (10.8)5 (8.9)2 (22.2)71138274Total130098931110 (1.0)10 (1.0)02 (0.6)02 (0.6)29 (2.2)24 (2.4)5 (1.6)76155017562Values in parenthesis represent mortality %*T/L* thoracoscopic and/or laparoscopic **Table 37**Malignant esophageal diseases (histologic classification)Resection (+)Resection (−)TotalCarcinomas7616238810,004 1. Squamous cell carcinoma683622799115 2. Basaloid(-squamous) carcinoma68876 3. Carcinosarcoma36440 4. Adenocarcinoma in the Barrett's esophagus30626332 5. Other adenocarcinoma28132313 6. Adenosquamous carcinoma28230 7. Mucoepidermoid carcinoma909 8. Adenoid cystic carcinoma101 9. Endocrine cell carcinoma352257 10. Undifferentiated carcinoma4711 11. Others12820Other malignancies41344 1. Malignant non-epithelial tumors14115 2. Malignant melanoma22224 3. Other malignant tumors505Not specified202646Total7677241710,094Resection: including endoscopic resection **Table 38**Malignant esophageal disease (clinical characteristics)Operation (+)EMR or ESDOperation (−)TotalCases30-day mortalityHospital mortalityTotalHospitalAfter discharge1. Esophageal cancer582441 (0.7)41 (0.7)0114 (2.0)1853241710,094Location0 (1) Cervical esophagus1950003 (1.5)80178453 (2) Thoracic esophagus475832 (0.7)32 (0.7)098 (2.1)133218477937 (3) Abdominal esophagus6056 (1.0)6 (1.0)09 (1.5)7066741 (4) Multiple cancers2622 (0.8)2 (0.8)03 (1.1)13059451 (5) Others/not described41 (25.0)1 (25.0)01 (25.0)241267512Tumor depth (A) Superficial cancer (T1)17998 (0.4)8 (0.4)019 (1.1)17571923748  *Mucosal cancer* (*T1a*)*4251* (*0.2*)*1* (*0.2*)*02* (*0.5*)*1285241734* (B) Advanced cancer (T2--T4)402533 (0.8)33 (0.8)094 (2.3)121986224 (C) Not specified0000095271222. Multiple primary cancers9846 (0.6)6 (0.6)019 (1.9)35532316621) Synchronous5534 (0.7)4 (0.7)011 (2.0)146174873 (1) Head and neck16600006750283 (2) Stomach1971 (0.5)1 (0.5)02 (1.0)4365305 (3) Others1573 (1.9)3 (1.9)08 (5.1)2349229 (4) Triple cancers24000013643 (5) Unknown90001 (11.1)04132) Metachronous4282 (0.5)2 (0.5)08 (1.9)209149786 (1) Head and neck941 (1.1)1 (1.1)006340197 (2) Stomach1030002 (1.9)5931193 (3) Others1971 (0.5)1 (0.5)04 (2.0)5963319 (4) Triple cancers320001 (3.1)281272 (5) Unknown20001 (50.0)035Unknown30000000Values in parenthesis represent mortality %*EMR* endoscopic mucosal resection (including endoscopic submucosal dissection) Fig. 3Annual trend of in-patients with esophageal diseases. *EMR* endoscopic mucosal resection (including endoscopic submucosal dissection)

Among benign esophageal diseases (Table [36](#Tab50){ref-type="table"}), hiatal hernia, esophageal varices, esophagitis (including reflux esophagitis) and achalasia were the most common conditions in Japan. On the other hand, spontaneous rupture of the esophagus, benign esophageal tumors and congenital esophageal atresia were common diseases which were surgically treated as well as the above-mentioned diseases. The thoracoscopic and/or laparoscopic procedures have been widely adopted for benign esophageal diseases, in particular achalasia, hiatal hernia and benign tumors. Open surgery was performed in 989 patients with a benign esophageal disease, with 30-day mortality in 10 (1.0 %), while thoracoscopic and/or laparoscopic surgery was performed for 311 patients, with 2 (0.6 %) of the 30-day mortality The difference in these death rates between open and scopic surgery seem to be related the conditions requiring open surgery.

The majority of malignant diseases were carcinomas (Table [37](#Tab51){ref-type="table"}). Among esophageal carcinomas, the incidence of squamous cell carcinoma was 91.1 %, while that of adenocarcinomas including Barrett cancer was 6.4 %. The resection rate for patients with a squamous cell carcinoma was 75.0 %, while that for patients with an adenocarcinoma was 91.0 %.

According to location, cancer in the thoracic esophagus was the most common (Table [38](#Tab52){ref-type="table"}). Of the 3748 patients (37.1 % of total esophageal malignancies) having superficial esophageal cancers within mucosal and submucosal layers, 1799 (48.0 %) patients underwent esophagectomy, while 1757 (46.9 %) patients underwent EMR or ESD. The 30-day mortality rate and hospital mortality rate after esophagectomy for patients with a superficial cancer were 0.2 and 0.5 % respectively. Advanced esophageal cancer invading deeper than the submucosal layer was observed in 6224 (61.7 %) patients. Of the 6224 patients with advanced esophageal cancer, 4025 (64.7 %) underwent esophagectomy, with 0.8 % of the 30-day mortality rate, and with 2.3 % of the hospital mortality rate.

Multiple primary cancers were observed in 1662 (16.5 %) of all the 10,094 patients with esophageal cancer. Synchronous cancer was found in 873 (52.5 %) patients, while metachronous cancer (found before esophageal cancer) was observed in 786 (47.3 %) patients. The stomach is the commonest site for both synchronous and metachronous malignancy followed by head and neck cancer (Table [38](#Tab52){ref-type="table"}).

Among esophagectomy procedures, transthoracic esophagectomy through right thoracotomy was the most commonly adopted for patients with a superficial cancer as well as for those with an advanced cancer (Table [39](#Tab53){ref-type="table"}). Transhiatal esophagectomy commonly performed in Western countries was adopted in only 4.6 % of patients having a superficial cancer who underwent esophagectomy and in 1.5 % of those having an advanced cancer in Japan. The thoracoscopic and/or laparoscopic esophagectomy were adopted for 1049 patients (58.3 %) with a superficial cancer, and for 1326 patients (32.9 %) with an advanced cancer. The number of cases of thoracoscopic and/or laparoscopic surgery for superficial or advanced cancer has been increasing for these several years (Fig. [4](#Fig4){ref-type="fig"}).**Table 39**Malignant esophageal disease (surgical procedures)CasesOperation (+)Thoracoscopic and/or laparoscopic procedureEMR or ESD30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeSuperficial cancer (T1)*17998* (*0.4*)*019* (*1.1*)*10491* (*0.1*)*06* (*0.6*)1757 *Mucosal cancer* (*T1a*)*4251* (*0.2*)*02* (*0.5*)*2120001285*Esophagectomy*17998* (*0.4*)*019* (*1.1*)*10491* (*0.1*)*06* (*0.6*)1757 (1) Transhiatal esophagectomy83001 (1.2)18000 (2) Transthoracic (rt.) esophagectomy and reconstruction14516 (0.4)015 (1.0)8861 (0.1)05 (0.6) (3) Transthoracic (lt.) esophagectomy and reconstruction6500020000 (4) Cervical esophageal resection and reconstruction90002000 (5) Two stage operation181 (5.6)02 (11.1)12001 (8.3) (6) Others119000108000 (7) Not specified541 (1.9)01 (1.9)3000Advanced cancer (T2--T4)Esophagectomy*402533* (*0.8*)*094* (*2.3*)*132614* (*1.1*)*035* (*2.6*)1 (1) Transhiatal esophagectomy601 (1.7)04 (6.7)6000 (2) Transthoracic (rt.) esophagectomy and reconstruction334025 (0.7)069 (2.1)117311 (0.9)029 (2.5) (3) Transthoracic (lt.) esophagectomy and reconstruction1583 (1.9)03 (1.9)41 (25.0)01 (25.0) (4) Cervical esophageal resection and reconstruction105002 (1.9)5000 (5) Two stage operation971 (1.0)010 (10.3)20002 (10.0) (6) Others/not specified2413 (1.2)06 (2.5)1142 (1.8)03 (2.6) (7) Not specified240004000(Depth not specified)*00005001* (20.0)95Combined resection of other organs*2814* (*1.4*)*08* (*2.8*) (1) Aorta2000 (2) Trachea, bronchus44001 (2.3) (3) Lung77104 (5.2) (4) Others1563 (1.9)03 (1.9)Unknown2000Salvage surgery*2342* (*0.9*)*014* (*6.0*)*38002* (*5.3*)34Values in parenthesis represent mortality % Fig. 4Annual trend of video-assiste d esophagectomy for esophageal malignancy

Combined resection of the neighboring organs during resection of an esophageal cancer was performed in 281 patients (Tables [39](#Tab53){ref-type="table"}, [40](#Tab54){ref-type="table"}). Resection of the aorta together with the esophagectomy was performed in 2 cases. Tracheal and/or bronchial resection combined with esophagectomy was performed in 44 patients, with the 30-day mortality rate at 0 % and the hospital mortality rate at 2.3 %. Lung resection combined with esophagectomy was performed in 77 patients, with the 30-day mortality rate at 1.3 % and the hospital mortality rate at 5.2 %.**Table 40**Mortality after combined resection of the neighboring organsYearEsophagectomyCombined resectionAortaTracheobronchusLungOthersabc (%)abc (%)abc (%)abc (%)abc (%)199641941202.867342.862400.005024.007845.13199744411272.86100.0034514.715611.799433.19199848781362.79400.002900.007411.3512821.56199950151162.31500.002328.706800.0012210.8220005350811.51200.002328.706900.009611.04200155211101.99100.002613.858333.619922.0220024904661.353133.3320210.006300.006311.5920034639450.97000.002428.335800.008811.1420044739641.35200.001700.005958.4711921.6820055163521.01100.001119.096711.497311.3720065236631.20000.001700.006223.2312232.4620074990601.20000.002514.004412.2713821.4520085124631.23000.001715.884812.0818500.0020095260631.20000.0019210.535823.4521131.4220105180450.87200.003300.005800.0024552.0420115430380.70400.002600.004100.0017952.7920126055470.78200.002314.356900.0024010.4220135824410.70200.004400.007711.3015631.92Total91,94310401.1326415.38273165.86753162.121220231.89*a* number of patients who underwent the operation, *b* number of patients died within 30 days after operation, *c* % ratio of b/a, *i.e.*, direct operative mortality

Salvage surgery after definitive (chemo-) radiotherapy was performed in 234 patients, with the 30-day mortality rate at 0.9 % and with the hospital mortality rate at 6.0 % (Table [39](#Tab53){ref-type="table"}).

Lastly, in spite of the efforts of the Committee to cover wider patient populations to this annual survey, the majority of the institutions which responded to the questionnaire were the departments of thoracic or esophageal surgery. It should be noted that larger number of patients with esophageal diseases should have been treated medically and endoscopically. We should continue our effort for complete survey through more active collaboration with the Japan Esophageal Society and other related societies.
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